BMS-963272 + rosuvastatin

BMS-963272 + rosuvastatin is a combination of two drugs investigated in clinical studies for potential drug-drug interactions. **BMS-963272** is an orally administered, potent, and selective inhibitor of **MGAT2** (alpha-1,6-mannosyl-glycoprotein 2-beta-N-acetylglucosaminyltransferase), developed for the treatment of metabolic disorders such as obesity and nonalcoholic fatty liver disease. **Rosuvastatin** is an HMG-CoA reductase inhibitor (statin) used to lower cholesterol and prevent cardiovascular disease. No fixed-dose commercial combination exists for these two agents; the combination studied here is investigational and was assessed to examine potential pharmacokinetic interactions in healthy participants and their safety and tolerability[1][2][5][7].